Alnylam, Medtronic Release Preclinical Data from Huntington's Disease Program

The newly released preclinical data shows that direct delivery of huntingtin-targeted siRNAs induced "robust silencing" of the huntingtin mRNA, with the effect observed at "substantial distances from the infusion site," the companies said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.